Pharma Focus Asia

Novo Nordisk Breaks Ground on $2 billion Production Facility in Clayton, North Carolina

Introduction:

Novo Nordisk broke ground on its new 2 billion US dollar production facility in Clayton, North Carolina.

Features:

The facility will produce active pharmaceutical ingredients (API) for a range of Novo Nordisk's current and future GLP-1 and insulin products. Once fully operational in 2020, Clayton will ensure production capacity for diabetes care products in the US for the decade ahead.

The new site is situated adjacent to Novo Nordisk's existing 42,000 m2 facility which assembles and packages FlexPen® and FlexTouch® prefilled insulin devices for the US market. The expansion is expected to create close to 700 new jobs and Novo Nordisk expects to create a significant employment effect during the construction period with up to 2,500 people working on the project at its peak.

Specifications:

Company NameNovo Nordisk
LocationClayton, North Carolina
TypeNew Production Facility
Estimated Investment$1.8 Billion
Jobs to be created700 Jobs
magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference